Levetiracetam in the treatment of epilepsy

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 3, 2008, Pages 507-523

  Abou Khalil, Bassel ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drugs; Efficacy; Epilepsy; Levetiracetam; Long term therapy; Safety; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN PROTEIN; CARBAMAZEPINE; CLONAZEPAM; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MESUXIMIDE; NEUROTRANSMITTER; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; WARFARIN; ZONISAMIDE;

ABSENCE; ADD ON THERAPY; AGGRESSION; AGITATION; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; BENIGN CHILDHOOD EPILEPSY; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONGENITAL MALFORMATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INDUCTION; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; HOSTILITY; HUMAN; INSOMNIA; IRRITABILITY; LANDAU KLEFFNER SYNDROME; LEARNING DISORDER; LENNOX GASTAUT SYNDROME; LOW BACK PAIN; LOW BIRTH WEIGHT; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MENTAL INSTABILITY; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NERVOUSNESS; NONHUMAN; PATIENT COMPLIANCE; PERSONALITY DISORDER; PHOTOSENSITIVE EPILEPSY; PSYCHOSIS; QUALITY OF LIFE; SEIZURE; SHORT TERM MEMORY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TERATOGENICITY; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEST SYNDROME;

EID: 47849132960     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s2937     Document Type: Article

References (160)

1. Abend NS, Florance N, Finkel RS et al. 2008. Intravenous levetiracetam terminates refractory focal status epilepticus. Neurocrit Care. Jan 8 [Epub ahead of print].
2. Abou-Khalil B, Hemdal P, Privitera MD. 2003. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day-1. in adult patients with refractory epilepsy. Seizure, 12:141-9.
3. Abou-Khalil B, Lazenby B. 2003. Long-term experience with levetiracetam. Epileptic Disord, 5(Suppl 1):S33-7.
4. Aeby A, Poznanski N, Verheulpen D, et al. 2005. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases. Epilepsia, 46:1937-42.
5. Alehan F, Ozcay F, Haberal M. 2008. The use of levetiracetam in a child with nonconvulsive status epilepticus. J Child Neurol, 23:331-3.
6. Allegaert K, Lewi L, Naulaers G, et al. 2006. Levetiracetam pharmacokinetics in neonates at birth. Epilepsia, 47:1068-9.
7. Andermann E, Andermann F, Meyvisch P, et al. 2005. Seizure control with levetiracetam in juvenile myoclonic epilepsies. Epilepsia, 46(Suppl 8):205.
8. Arif H, Buchsbaum R, Weintraub D, et al. 2007. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 68:1701-9.
9. Atefy R, Tettenborn B. 2005. Nonconvulsive status epilepticus on treatment with levetiracetam. Epilepsy Behav, 6:613-16.
10. Baulac M, Brodie MJ, Elger CE, et al. 2007. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia, 48:589-92.
11. Bazil CW, Rose A, Resor S, et al. 2002. Levetiracetam maybe more effective for late-onset partial epilepsy. Arch Neurol, 59:1905-8.
12. Beghi E Gatti G, Tonini C, et al. 2003. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res, 57:1-13.
13. Bello-Espinosa LE, Roberts SL. 2003. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases. Seizure, 12:157-9.
14. Ben-Menachem E, Edrich P, Van Vleymen B, et al. 2003. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res, 53:57-64.
15. Ben-Menachem E, Falter U. 2000. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia, 41:276-83.
16. Ben-Menachem E, Gilland E. 2003. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure, 12:31-5.
17. Berkovic SF, Knowlton RC, Leroy RF, et al. 2007. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology, 69:1751-60.
18. Betts T, Waegemans T, Crawford P. 2000. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure, 9:0-7.
19. Betts T, Yarrow H, Greenhill L, et al. 2003. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Seizure, 12:36-40.
20. Boccella P, Striano P, Zara F, et al. 2003. Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters. Clin Neurol Neurosurg, 106:5-9.
21. Brodie MJ, Perucca E, Ryvlin P, et al. 2007. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology, 68:402-8.
22. Brodtkorb E, Klees TM, Nakken KO, et al. 2004. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav, 5:31-5.
23. Browne TR, Szabo GK, Leppik IE, et al. 2000. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol, 40:90-5.
24. Capovilla G, Beccaria F, Cagdas S, et al. 2004. Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleep. Acta Neurol Scand, 110:44-7.
25. Cereghino JJ, Biton V, Abou-Khalil B, et al. 2000. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology, 55:36-42.
26. Chabolla DR, Harnois DM, Meschia JF. 2003. Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc, 35:480-1.
27. Commission. 1981. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 22:89-501.
28. Commission 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 30:389-99.
29. Coppola G, Franzoni E, Verrotti A, et al. 2007. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes BECTS: an open-label, parallel group trial. Brain Dev, 29:81-4.
30. Coppola G, Mangano S, Tortorella G, et al. 2004. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res, 59:5-42.
31. Coupez R, Nicolas JM, Browne TR. 2003. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia, 44:71-8.
32. Cramer JA, Arrigo C, Van Hammee G, et al. 2000. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia, 41:68-74.
33. Cramer JA, De Rue K, Devinsky O, et al. 2003. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav, 4:24-32.
34. Cramer JA, Van Hammee G. 2003. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav, 4:118-23.
35. Crest C, Dupont S, Leguern E, et al. 2004. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology, 62:40-3.
36. De Los Reyes EC, Sharp GB, Williams JP, et al. 2004. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol, 30:54-6.
37. Depondt C, Yuen AW, Bell GS, et al. 2006. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry, 77:01-3.
38. Di Bonaventura C, Fattouch J, Mari F, et al. 2005. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord, 7:31-5.
39. Di Bonaventura C, Mari F, Fattouch J, et al. 2006. Use of levetiracetam in treating epilepsy associated with other medical conditions. Acta Neurol Scand, 113:2-6.
40. Engel J Jr. 2001. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia, 42:96-803.
41. Falip M, Carreno M, Amaro S, et al. 2006. Use of levetiracetam in hospitalized patients. Epilepsia, 47:186-8.
42. Farooq MU, Naravetla B, Majid A, et al. 2007. IV levetiracetam in the management of non-convulsive status epilepticus. Neurocrit Care, 7:36-9.
43. Ferrendelli JA, French J, Leppik I, et al. 2003. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav, 4:02-9.
44. French J. 2001. Use of levetiracetam in special populations. Epilepsia, 42(Suppl 4):40-3.
45. French J, Arrigo C. 2005. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia, 46:324-6.
46. French J, di Nicola S, Arrigo C. 2005. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia, 46:1304-7.
47. French J, Edrich P, Cramer JA. 2001. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res, 47:77-90.
48. French JA, Kanner AM, Bautista J et al. 2004. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 62:1261-73.
49. Frucht SJ, Louis ED, Chuang C, et al. 2001. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology, 57:1112-4.
50. Gelisse P, Crespel A, Genton P, et al. 2003. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand, 107:302-3.
51. Genton P, Gelisse P. 2001. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology, 57:1144-5.
52. Genton P, Sadzot B, Fejerman N, et al. 2006. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scand, 113:387-94.
53. Glass GA, Stankiewicz J, Mithoefer A, et al. 2005. Levetiracetam for seizures after liver transplantation. Neurology, 64:1084-5.
54. Glauser TA, Ayala R, Elterman RD, et al. 2006. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology, 66:1654-60.
55. Glauser TA, Mitchell WG, Weinstock A, et al. 2007. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia, 48:1117-42.
56. Glauser TA, Pellock JM, Bebin EM, et al. 2002. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia, 43:518-24.
57. Gomer B, Wagner K, Frings L, et al. 2007. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav, 10:486-94.
58. Goraya JS, Khurana DS, Valencia I, et al. 2008. Intravenous Levetiracetam in Children With Epilepsy. Pediatr Neurol, 38:177-80.
59. Hirsch LJ, Arif H, Buchsbaum R,et al. 2007. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia, 48:1351-9.
60. Hunt S, Craig J, Russell A, et al. 2006. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology, 67:1876-9.
61. Imperiale D, Bortolotto S, Cucatto A, et al. 2003. Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease. Eur Neurol, 49:189-90.
62. Janszky J, Pannek HW, Janszky I, et al. 2005. Failed surgery for temporal lobe epilepsy: Predictors of long-term seizure-free course. Epilepsy Res, 64:35-44.
63. Johannessen SI, Helde G, Brodtkorb E. 2005. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia, 46:775-7.
64. Kaminski RM, Matagne A, Leclercq K, et al. 2008. SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 54:715-20.
65. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, et al. 1996. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res, 25:225-30.
66. Keswani SC, Kossoff EH, Krauss GL, et al. 2002. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry, 73:457-8.
67. Kinirons P, Mccarthy M, Doherty CP, et al. 2006. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure, 15:387-92.
68. Kinrions P, Ibrahim N, Murphy K, et al. 2003. Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology, 60:1394-5.
69. Klitgaard H, Matagne A, Gobert J, et al. 1998. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol, 353:191-206.
70. Knake S, Gruener J, Hattemer K, et al. 2007. Intravenous levetiracetam in the treatment of benzodiazepine-refractory status epilepticus. J Neurol Neurosurg Psychiatry. Sep26 [Epub ahead of print].
71. Kossoff EH, Bergey GK, Freeman JM, et al. 2001. Levetiracetam psychosis in children with epilepsy. Epilepsia, 42:1611-3.
72. Kossoff EH, Boatman D, Freeman JM. 2003. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav, 4:571-5.
73. Krakow K, Walker M, Otoul C, et al. 2001. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology, 56:1772-4.
74. Krauss GL, Bergin A, Kramer RE, et al. 2001. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology, 56:411-2.
75. Krauss GL, Betts T, Abou-Khalil B, et al. 2003. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure, 12:617-20.
76. Kuba R, Novotna I, Brazdil M, et al. 2006. Long-term levetiracetam treatment of epilepsy patients: clinical audit. Epilepsy Res, 72:111-9.
77. Kumar SP, Smith PE. 2004. Levetiracetam as add-on therapy in generalised epilepsies. Seizure, 13:475-7.
78. Kwan P, Brodie MJ. 2000a. Early identification of refractory epilepsy. N Engl J Med, 342:314-9.
79. Kwan P, Brodie MJ. 2000b. Epilepsy after the first drug fails: substitution or add-on? Seizure, 9:464-8.
80. Labate A, Colosimo E, Gambardella A, et al. 2006. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure, 15:214-8.
81. Lagae L, Buyse G, Deconinck A, et al. 2003. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol, 7:123-8.
82. Lambrechts DA, Sadzot B, van Paesschen W, et al. 2006. Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands. Seizure, 15:434-42.
83. Lancelin F, Franchon E, Kraoul L, et al. 2007. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit, 29:576-83.
84. Lawlor KM, Devlin AM. 2005. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol, 9:19-22.
85. Leppik I, Morrell M, Godfroid P, et al. 2003a. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia, 44:1350-2.
86. Leppik IE, Biton V, Sander JW, et al. 2003b. Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials. Epilepsia, 44:1585-7.
87. Levy RH, Ragueneau-Majlessi I, Baltes E. 2001. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res, 46:93-9.
88. Lim LL, Ahmed A. 2005. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord, 11, 135-7.
89. Long L. 2003. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav, 4:447-8.
90. Loscher W, Honack D. 1993. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol, 232:147-58.
91. Loscher W, Honack D. 2000. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia, 41:1499-506.
92. Loscher W, Schmidt D. 2006. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia, 47:1253-84.
93. Lukyanetz EA, Shkryl VM, Kostyuk PG. 2002. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia, 43:9-18.
94. Lynch BA, Lambeng N, Nocka K, et al. 2004. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA, 101:9861-6.
95. Magaudda A, Gelisse P, Genton P. 2004. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia, 45:678-81.
96. Mancuso M, Galli R, Pizzanelli C, et al. 2006. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci, 243:97-9.
97. Marson AG, Hutton JL, Leach JP, et al. 2001. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res, 46:259-70.
98. Maschio M, Albani F, Baruzzi A, et al. 2006. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol, 80:97-100.
99. May TW, Rambeck B, Jurgens U. 2003. Serum Concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit, 25:690-9.
100. Meador KJ, Gevins A, Loring DW, et al. 2007. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology, 69:2076-84.
101. Morrell MJ, Leppik I, French J, et al. 2003. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res, 54:153-61.
102. Motamedi M, Nguyen DK, Zaatreh M, et al. 2003. Levetiracetam efficacy in refractory partial-onset seizures, especially after failed epilepsy surgery. Epilepsia, 44:211-4.
103. Mula M, Trimble MR, Sander JW. 2004. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure, 13:55-7.
104. Mula M, Trimble MR, Sander JW. 2007. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia, 48:2322-6.
105. Mula M, Trimble MR, Yuen A, et al. 2003. Psychiatric adverse events during levetiracetam therapy. Neurology, 61:704-6.
106. Nakken KO, Eriksson AS, Lossius R, et al. 2003. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure, 12:42-6.
107. Newton HB, Dalton J, Goldlust S, et al. 2007. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol, 84:293-6.
108. Newton HB, Goldlust SA, Pearl D. 2006. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol, 78:99-102.
109. Nicolas JM, Collart P, Gerin B, et al. 1999. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos, 27:250-4.
110. Nicolson A, Lewis SA, Smith GF. 2004. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology, 63:568-70.
111. +. current in pyramidal neurones of rat hippocampal slices. Neurosci Lett, 306:5-8.
112. Noachtar S, Andermann E, Meyvisch P, et al. 2008. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology, 70:607-16.
113. Otoul C, Arrigo C, Rijckevorsel KV, et al. 2005. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol, 28:72-8.
114. Papacostas S, Kkolou E, Papathanasiou E. 2007. Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci, 29:164-6.
115. Patel NC, Landan IR, Levin, J, et al. 2006. The use of levetiracetam in refractory status epilepticus. Seizure, 15:137-41.
116. Patsalos PN. 2000. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther, 85:77-85.
117. Patsalos PN. 2003. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol, 25:123-9.
118. Patsalos PN. 2004. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet, 43: 707-24.
119. Patsalos PN, Perucca E. 2003. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol, 2:473-81.
120. Pellock JM, Glauser TA, Bebin EM, et al. 2001. Pharmacokinetic study of levetiracetam in children. Epilepsia, 42:1574-9.
121. Perucca E, Gidal BE, Baltes E. 2003. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res, 53:47-56.
122. Prasad A, Kuzniecky RI, Knowlton RC, et al. 2003. Evolving anti-epileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol, 60:1100-5.
123. Radtke PA. 2001. Pharmacokinetics of levetiracetam. Epilepsia, 42(Suppl 4):24-7.
124. Ragueneau-Majlessi I, Levy RH, Janik F. 2002. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia, 43:697-702.
125. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. 2001. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res, 47:55-63.
126. Ramael S, Daoust A, Otoul C, et al. 2006a. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia, 47:1128-35.
127. Ramael S, De Smedt F, Toublanc N, et al. 2006b. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther, 28:734-44.
128. Renganathan R, Delanty N. 2003. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J, 79:78-80.
129. Rigo JM, Hans G, Nguyen L, et al. 2002. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol, 136:659-72.
130. Rossetti AO, Bromfield EB. 2005. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol, 54:34-8.
131. Rossetti AO, Bromfield EB. 2006. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav, 8:651-4.
132. Ruegg S, Naegelin Y, Hardmeier M, et al. 2008. Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. Epilepsy Behav.
133. Rupprecht S, Franke K, Fitzek S, et al. 2007. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res, 73:238-44.
134. Schachter SC. 2007. Currently available antiepileptic drugs. Neurotherapeutics, 4:4-11.
135. Schauer R, Singer M, Saltuari L, et al. 2002. Suppression of cortical myoclonus by levetiracetam. Mov Disord, 17:411-5.
136. Schulze-Bonhage A, Hefft S, Oehl B. 2007. Termination of complex partial status epilepticus by intravenous levetiracetam - a case report. J Neurol Neurosurg Psychiatry. Mar 12 [Epub ahead of print].
137. Selwa LM, Schmidt SL, Malow BA, et al. 2003. Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Fpilepsia, 44:1568-72.
138. Sharpe DV, Patel AD, Abou-Khalil B, et al. 2008. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure, 17:64-8.
139. Shorvon SD, Lowenthal A, Janz D, et al. 2000. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia, 41:1179-86.
140. Specchio LM, Gambardella A, Giallonardo AT, et al. 2006. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res, 71:32-9.
141. Stefan H, Wang-Tilz Y, Pauli E, et al. 2006. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis TISA. Epilepsia, 47:516-22.
142. Steinhoff BJ, Trinka E, Wieser HG. 2005. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Seizure, 14:490-6.
143. Striano P, Coppola A, Pezzella M, et al. 2007. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology, 69:250-4.
144. Striano F, Manganelli F, Boccella P, et al. 2005. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord, 20:1610-4.
145. Szaflarski JP, Meckler JM, Szaflarski M, et al. 2007. Levetiracetam use in critically ill patients. Neurocrit Care, 7:140-7.
146. ten Berg K, Samren EB, van Oppen AC, et al. 2005. Levetiracetam use and pregnancy outcome. Reprod Toxicol, 20, 175-8.
147. Tomson T, Palm R, Kallen K, et al. 2007. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia, 48:1111-6.
148. Trabacca A, Profice P, Costanza MC, et al. 2007. Levetiracetam in nonconvulsive status epilepticus in childhood: a case report. J Child Neurol, 22:639-41.
149. Tsai JJ, Yen DJ, Hsih MS, et al. 2006. Efficacy and safety of levetiracetam up to 2000 mg/day. in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia, 47:72-81.
150. Verrotti A, Coppola G, Manco R, et al. 2007. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures. Seizure, 16:271-5.
151. Wagner GL, Wilms EB, Van Donselaar CA, et al. 2003. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure, 12:585-6.
152. Westin AA, Reimers A, Helde G, et al. 2008. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure, 17:192-8.
153. Wheless JW, Ng YT. 2002. Levetiracetam in refractory pediatric epilepsy. J Child Neurol, 17:413-5.
154. White JR, Walczak TS, Leppik IE, et al. 2003. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology, 61:1218-21.
155. Wirrell EC. 1998. Benign epilepsy of childhood with centrotemporal spikes. Epilepsia, 39(Suppl 4):S32-41.
156. Yang XF, Weisenfeld A, Rothman SM. 2007. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia, 48-1861-9.
157. Youroukos S, Lazopoulou D, Michelakou D, et al. 2003. Acute psychosis associated with levetiracetam. Epileptic Disord, 5:117-9.
158. Zaatreh MM. 2005. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol, 28:243-4.
159. Zaccara G, Messori A, Cincotta M, et al. 2006. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand, 114:157-68.
160. Zhou B, Zhang Q, Tian L, et al. 2008. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav, 12:305-10.